Why is Poxet 60 mg classified as a phosphodiesterase type 5 (PDE5) inhibitor?

[avynaa]

Poxet 60 mg is not classified as a phosphodiesterase type 5 (PDE5) inhibitor. Instead, it belongs to a different class of medications known as selective serotonin reuptake inhibitors (SSRIs). The active ingredient in Poxet is dapoxetine, which is an SSRI. PDE5 Inhibitors Medications in this class, such as sildenafil, tadalafil, and vardenafil, are primarily used to treat erectile dysfunction (ED). They work by inhibiting the enzyme phosphodiesterase type 5, which is responsible for breaking down cyclic guanosine monophosphate (cGMP) in the erectile tissue of the penis. By inhibiting PDE5, these medications increase the levels of cGMP, which leads to relaxation of blood vessels and improved blood flow to the penis, facilitating erections. SSRIs (Selective Serotonin Reuptake Inhibitors) Poxet 60 mg, the active ingredient in Poxet, is an SSRI used to treat premature ejaculation (PE). SSRIs primarily affect the levels of serotonin in the brain by inhibiting its reuptake. In the context of PE, dapoxetine is thought to exert its effects on ejaculation by modulating the serotonin neurotransmitter system, which can help delay ejaculation and improve control over ejaculation timing. Poxet 60 mg is classified as an SSRI, not a PDE5 inhibitor. It is specifically designed to address the issue of premature ejaculation by affecting the serotonin system in the brain, rather than targeting blood flow to the penis, as PDE5 inhibitors do for erectile dysfunction. These medications serve different purposes and are used for distinct sexual health concerns.